Patient Blood Management – Past, Present and Future
Patient Blood Management in Surgery – Preoperative Preparation
Patient Blood Management – Does It Work in Children Too?
Iron Therapy in Special Indications
Underrated Measures in Patient Blood Management
Emergency Care of Patients Receiving Antithrombotics
Best Posters – Presentations and Awards
Red Blood Cell Transfusion – How Low Can/Should We Go?
Anticoagulation
Stop the Bleeding!
Safety of Blood and Blood Products
Breaking News
20th Annual NATA Symposium

CSL BEHRING SATELLITE SYMPOSIUM

GOAL-DIRECTED THERAPY OF BLEEDING

Friday, April 5th 2019 / 12:50–13:50 h
Maritim proArte Hotel Berlin
Hall B / C
Berlin / Germany

CHAIR: JENS MEIER, Austria

In emergency patients
HERBERT SCHÖCHL, Austria

In perioperative setting
DANIEL DIRKMANN, Germany
SIMPLY GENIUS

autoLogIQ™
Autotransfusion System

INTELLIGENT
EASY
ADAPTABLE

One bowl size. One kit. One button to push to get high quality blood delivered, automatically, case after case. All in an ergonomically designed unit that’s easy to move and fits into virtually any operating space. Simply genius.

For more information contact your local Medtronic sales representative.
Dear Colleague,

On behalf of the NATA board of directors, it is our pleasure to welcome you to the 20th NATA Symposium on Patient Blood Management, Haemostasis and Thrombosis that is taking place in Berlin on April 4-5, 2019.

Every year, NATA attracts a wide international and multidisciplinary audience from more than 40 countries. The scientific programme covers a wide range of topics related to anaemia, patient blood management (PBM), critical bleeding and thrombosis.

During this year’s anniversary symposium, a number of hot topics related to the concept of PBM and its implementation will be discussed. What is the evidence base for PBM? How to implement preoperative preparation? Does the PBM concept work in children too? What are the most underrated PBM measures?

Thematic sessions will be dedicated to the management of iron deficiency, anaemia tolerance in special populations, the safety of blood and blood products, emergency care of patients on antithrombotic agents, treatment of severe surgery- or trauma-associated bleeding, and prevention of venous thrombosis. New, yet unpublished evidence will be presented by several speakers.

The programme also features new recommendations developed by two NATA task forces:

• PBM for neonates and children undergoing cardiac surgery
• PBM in obstetrics: prevention and treatment of postpartum haemorrhage

Every year, a high number of excellent abstracts are submitted for presentation. We encourage delegates to visit e-poster stations during the coffee breaks. In addition, the presenters of the 8 best-rated abstracts have been invited to give a 5-minute presentation followed by a 3-minute discussion during the session “Best Posters – Presentations and Awards”. The 3 best presentations will be selected by audience voting using the “NATA Forum” App.

If you find it frustrating to choose between two parallel sessions, please keep in mind that recorded presentations are posted on the NATA Forum App shortly after each session!

More than ever, the annual NATA symposium will provide a unique opportunity for stimulating and constructive exchanges across different specialties involved in PBM.

Yours sincerely,

Charles-Marc Samama
NATA Chair

Jens Meier
Chair, NATA Scientific Committee
About nata

nata: Who Are We?

NATA, the Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis (formerly the Network for the Advancement of Transfusion Alternatives), is an independent medical association that was created in 1998.

NATA is unique in that it provides a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals interested in promoting best clinical practice in the management of anaemia and iron deficiency, critical bleeding and thrombosis.

NATA’s Educational Activities

Annual Symposium and Regional Symposia

NATA has organised 19 annual symposia in Europe since 2000, with an average attendance ranging between 500 and 600 delegates from around 40 countries. NATA has also organised several regional symposia and a number of sessions or participations at other societies’ international and local congresses.

Expert Meetings and Guidelines

NATA has organised expert meetings that have led to the publication of a Seminars in Hematology supplement on the role of intravenous iron in anaemia management, a consensus statement on the role of intravenous iron in perioperative anaemia management (Beris P et al. Br J Anaesth 2008;100:599-604), and guidelines for the detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient (Goodnough LT et al. Br J Anaesth 2011;106:13-22).

A series of expert meetings on patient blood management in obstetrics, organised in collaboration with other medical associations, is underway. A consensus statement dedicated to the management of anaemia and haematocrit deficiencies in pregnancy and in the post-partum period was published in Transfusion Medicine (Muñoz M et al. Transfus Med 2018;28:22-39). A second one, which provides recommendations on the prevention and treatment of postpartum haemorrhage, has been published online recently (Muñoz M et al. Blood Transfus 2019 Feb 6 [Epub ahead of print])

A NATA task force has developed the first guidelines on patient blood management for neonates and children undergoing cardiac surgery (Faraoni D et al. J Cardiothorac Vasc Anesth 2019 [Accepted for publication]).
**NATA’s website** ([www.nataonline.com](http://www.nataonline.com)) provides educational material and news free of charge. A weekly review of the literature is performed and selected articles are graded and summarised by scientific committee members. Comments and news are also disseminated through NATA’s LinkedIn group and twitter.

**E-learning** is emerging as an attractive tool for continuing medical education. In 2016 NATA launched an e-learning programme hosted on a platform connected to Nataonline ([www.nata-education.com](http://www.nata-education.com)). The first completed module, developed under the supervision of three members of NATA’s scientific committee (Manuel Muñoz, Elvira Bisbe and Jean-François Hardy), is entitled, Detection, Evaluation and Treatment of Preoperative Anaemia. The plan is to develop a series of CME-accredited e-learning modules covering NATA’s main topics of interest.

**NATA’s first webinar**, Emergency Care of Patients Treated with Direct Oral Anticoagulants, was held on March 27, 2019, and has been submitted for CME accreditation as an e-learning course. This 1-hour educational webinar, chaired by Charles-Marc Samama with lectures by Oliver Grottke and Sam Schulman, provides a comprehensive, state-of-the-art overview of the available evidence on the management of bleeding and emergency procedures in patients treated with direct oral anticoagulants (DOACs).
CME Accreditation

The 20th Annual NATA Symposium is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The 20th Annual NATA Symposium has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 10 European CME credits (ECMEC®s).

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

EACCME Credits

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

Ärztekammer Berlin

The 20th Annual NATA Symposium has been accredited by the Ärztekammer Berlin for a maximum of 6 CME credits.

CONGRESS INFORMATION

NATA Board of Directors

Chair
C.-M. Samama, Paris, France

Members
E. Bisbe, Barcelona, Spain
D. Faraoni, Toronto, ON, Canada
J.-F. Hardy, Montreal, QC, Canada
B. J. Hunt, London, UK
J. Meier, Linz, Austria
M. Muñoz, Málaga, Spain
T. Richards, Perth, WA, Australia

Scientific Committee

Chair
J. Meier, Linz, Austria

Members
M. Auerbach, Baltimore, MD, USA
E. Bisbe, Barcelona, Spain
J. L. Carson, New Brunswick, NJ, USA
D. Faraoni, Toronto, ON, Canada
T. Frietsch, Mannheim, Germany
B. Froessler, Adelaide, SA, Australia
J. A. García-Erce, Pamplona, Spain
L. T. Goodough, Stanford, CA, USA
T. Haas, Zurich, Switzerland
J.-F. Hardy, Montreal, QC, Canada
B. J. Hunt, London, UK
L. Kaufner, Berlin, Germany
S. Lasocki, Angers, France
J. H. Levy, Durham, NC, USA
J. Meier, Linz, Austria
K. Messmer, Munich, Germany
P. Meybohm, Frankfurt, Germany
F. Mohamed, Basingstoke, UK
M. Muñoz, Málaga, Spain
S. Ozawa, Englewood, NJ, USA
A. Pereira Saavedra, Barcelona, Spain
A. Perel, Tel Aviv, Israel
A. Pruss, Berlin, Germany
M. Ranucci, Milan, Italy
M. Reed, Newcastle upon Tyne, UK
T. Richards, Perth, WA, Australia
C.-M. Samama, Paris, France
P. Schlenke, Graz, Austria
H. Schochl, Vienna, Austria
E. Seifried, Frankfurt, Germany
A. Shander, Englewood, NJ, USA
D. R. Spahn, Zurich, Switzerland
D. Thomas, Swansea, Wales, UK
P. Tibi, Prescott, AZ, USA
T. Tomić Mahečić, Zagreb, Croatia
P. Van der Linden, Brussels, Belgium
A. Vlaar, Amsterdam, The Netherlands
C. von Heymann, Berlin, Germany
J. H. Waters, Pittsburgh, PA, USA

Faculty

J.-F. Baron, Paris, France
Y. Beguin, Liège, Belgium
E. Bisbe, Barcelona, Spain
D. Dirkmann, Essen, Germany
D. Faraoni, Toronto, ON, Canada
D. Fischer, Frankfurt, Germany
T. Frietsch, Mannheim, Germany
B. Froessler, Adelaide, SA, Australia
J. A. García-Erce, Pamplona, Spain
O. Grottke, Aachen, Germany
T. Haas, Zurich, Switzerland
J.-F. Hardy, Montreal, QC, Canada
A. Hofmann, Zurich, Switzerland
B. J. Hunt, London, UK
L. Kaufner, Berlin, Germany
S. Lasocki, Angers, France
J. H. Levy, Durham, NC, USA
J. Meier, Linz, Austria
K. Messmer, Munich, Germany
P. Meybohm, Frankfurt, Germany
F. Mohamed, Basingstoke, UK
M. Muñoz, Málaga, Spain
S. Ozawa, Englewood, NJ, USA
A. Pereira Saavedra, Barcelona, Spain
A. Perel, Tel Aviv, Israel
A. Pruss, Berlin, Germany
M. Ranucci, Milan, Italy
M. Reed, Newcastle upon Tyne, UK
T. Richards, Perth, WA, Australia
C.-M. Samama, Paris, France
P. Schlenke, Graz, Austria
H. Schochl, Vienna, Austria
E. Seifried, Frankfurt, Germany
A. Shander, Englewood, NJ, USA
D. R. Spahn, Zurich, Switzerland
D. Thomas, Swansea, Wales, UK
P. Tibi, Prescott, AZ, USA
T. Tomić Mahečić, Zagreb, Croatia
P. Van der Linden, Brussels, Belgium
A. Vlaar, Amsterdam, The Netherlands
C. von Heymann, Berlin, Germany
J. H. Waters, Pittsburgh, PA, USA

CME Accreditation

The 20th Annual NATA Symposium is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The 20th Annual NATA Symposium has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 10 European CME credits (ECMEC®s).

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

EACCME Credits

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

Ärztekammer Berlin

The 20th Annual NATA Symposium has been accredited by the Ärztekammer Berlin for a maximum of 6 CME credits.

Congress Venue
The 20th Annual NATA Symposium is taking place at Maritim proArte Hotel Berlin, Friedrichstraße 151, 10117 Berlin.

Delegate Registration & Information Desk
The registration and information desk is located on the 1st floor of Maritim proArte Hotel. Exhibitors should collect their exhibitor badges from this desk.

Opening Hours:  
Thursday, April 4 7:30–18:30  
Friday, April 5 8:30–16:30

Breaks
Breaks are scheduled as follows:  
10:30–11:10 on Thursday and Friday  
13:50–14:30 on Thursday and Friday  
16:00–16:40 on Thursday

NATA General Assembly
NATA members are invited to participate in the NATA General Assembly, which will take place on April 5 from 8:15 to 8:45 in Salon 3/4, First Floor.

Information for Speakers
Location: Salon 1, First Floor.

Information for E-poster Presenters
This year, NATA is moving to electronic posters. E-posters will be displayed on 4 e-poster stations (monitors) located in the exhibition area. Each e-poster will be visited by two moderators during one of the breaks of the symposium (see the schedule on page 14). Presenters will have 3 min for presentation and 2 min for discussion.

Free Wifi  
Network: NATA 2019 • Username: G-nata.zm@telekom.de • Password: nata2019
Welcome Address

Charles-Marc Samama, Paris, France - NATA Chair

Patient blood management – past, present and future

Charles-Marc Samama, Paris, France
Konrad Messmer, Munich, Germany

Patient blood management in surgery – preoperative preparation

Manuel Muñoz, Málaga, Spain
Lutz Kaufner, Berlin, Germany

Patient blood management – does it work in children too?

Beverley J. Hunt, London, UK
Sherri Ozawa, Englewood, NJ, USA

An anniversary NATA symposium – looking back on 20 years of PBM education

Jean-François Baron, Paris, France

PBM: an unproven concept? – the Frankfurt consensus conference

Erhard Seifried, Frankfurt, Germany

PBM: the standard of care!

Aryeh Shander, Englewood, NJ, USA

How to get started and overcome barriers to implementation?

Jean-François Hardy, Montreal, QC, Canada

Anaemia and iron deficiency screening and evaluation: a practical approach

Elvira Bisbe, Barcelona, Spain

Preoperative iron supplementation – when and how should it be done?

Toby Richards, Perth, WA, Australia

Is there a role for EPO in preoperative preparation?

Sigismond Lasocki, Angers, France

Perioperative transfusion triggers – all the same as in adults?

Philippe Van der Linden, Brussels, Belgium

Factor concentrates in paediatrics – top or flop?

Thorsten Haas, Zurich, Switzerland

PBM in paediatric cardiac surgery: NATA guidelines

David Faraoni, Toronto, ON, Canada

Lunchtime industry-sponsored satellite symposia and workshops
## SCIENTIFIC PROGRAMME

### THURSDAY, APRIL 4, 2019

#### 14:30-14:45
- **Iron deficiency: causes, global burden and treatment options**
  - Axel Hofmann, Zurich, Switzerland
- **Iron therapy in patients with cancer – ESMO clinical practice guidelines**
  - Yves Beguin, Liège, Belgium
- **Iron therapy in obstetrics – a global public health challenge**
  - Bernd Froessler, Adelaide, SA, Australia
- **The revival of oral iron: new agents, new dosing regimens**
  - Manuel Muñoz, Málaga, Spain

#### 14:30-14:45
- **Discussion**

#### 14:45-15:00
- **Cell salvage – still needed, or too expensive?**
  - Dafydd Thomas, Swansea, Wales, UK
- **Is haemodynamic monitoring a necessary cornerstone of PBM?**
  - Christian von Heymann, Berlin, Germany

#### 14:45-15:00
- **PBM measures in low-income countries**
  - Tina Tomić Mahečić, Zagreb, Croatia
- **Discussion**

#### 16:40-16:55
- **Assessing drug-induced bleeding risk and severity**
  - Jerrold H. Levy, Durham, NC, USA
- **Bleeding and emergency procedures in patients on vitamin K antagonists**
  - Beverley J. Hunt, London, UK
- **Bleeding and emergency procedures in patients on direct oral anticoagulants**
  - Charles-Marc Samama, Paris, France
- **Bleeding and emergency procedures in patients on antiplatelet agents**
  - David Farioni, Toronto, ON, Canada

#### 16:40-16:48
- **Case study of blood recycling device, Hemafuse, in urban Kenyan surgical theatres**
  - Katherine Kirsch, Nairobi, Kenya

#### 16:48-16:56
- **Calculating risks associated with preoperative anaemia and the health-economic footprint of patient blood management**
  - Thomas Drabinski, Kiel, Germany

#### 16:56-17:04
- **Efficacy and safety of fibrinogen concentrate vs cryoprecipitate in pseudomyxoma peritonei surgery: a prospective, randomised, controlled phase 2 study**
  - Faheez Mohamed, Basingstoke, UK

#### 17:04-17:12
- **Pharmacokinetics of enoxaparin after coronary artery bypass grafting. Randomised clinical trial**
  - Maria Parviainen, Tampere, Finland

#### 17:12-17:20
- **Impact of direct oral anticoagulant therapy on the management of hip fracture patients**
  - Nicolas Gautier, Charleroi, Belgium

#### 17:20-17:28
- **Impact of direct oral anticoagulant therapy on the management of hip fracture patients**
  - Nicolas Gautier, Charleroi, Belgium

#### 17:28-17:36
- **Poster awards**

### BREAK AND POSTER VISITS

**16:00-16:40**

**HALL BC**
- **Assessing drug-induced bleeding risk and severity**
  - Jerrold H. Levy, Durham, NC, USA
- **Bleeding and emergency procedures in patients on vitamin K antagonists**
  - Beverley J. Hunt, London, UK
- **Bleeding and emergency procedures in patients on direct oral anticoagulants**
  - Charles-Marc Samama, Paris, France
- **Bleeding and emergency procedures in patients on antiplatelet agents**
  - David Farioni, Toronto, ON, Canada

**16:40-16:48**
- **Case study of blood recycling device, Hemafuse, in urban Kenyan surgical theatres**
  - Katherine Kirsch, Nairobi, Kenya

**16:48-16:56**
- **Calculating risks associated with preoperative anaemia and the health-economic footprint of patient blood management**
  - Thomas Drabinski, Kiel, Germany

**16:56-17:04**
- **Efficacy and safety of fibrinogen concentrate vs cryoprecipitate in pseudomyxoma peritonei surgery: a prospective, randomised, controlled phase 2 study**
  - Faheez Mohamed, Basingstoke, UK

**17:04-17:12**
- **Pharmacokinetics of enoxaparin after coronary artery bypass grafting. Randomised clinical trial**
  - Maria Parviainen, Tampere, Finland

**17:12-17:20**
- **Impact of direct oral anticoagulant therapy on the management of hip fracture patients**
  - Nicolas Gautier, Charleroi, Belgium

**17:20-17:28**
- **Impact of direct oral anticoagulant therapy on the management of hip fracture patients**
  - Nicolas Gautier, Charleroi, Belgium

**17:28-17:36**
- **Poster awards**
Red blood cell transfusion – how low can/should we go?
Jean-François Hardy,
Montreal, QC, Canada
Peter Schlenke,
Graz, Austria

Anticoagulation
David Faraoni,
Toronto, ON, Canada
Beverley J. Hunt,
London, UK

Stop the bleeding!
Charles-Marc Samama,
Paris, France
Donat R. Spahn,
Zurich, Switzerland

Safety of blood and blood products
José A. García-Erce,
Pamplona, Spain
Axel Pruss,
Berlin, Germany

8:15-8:45 NATA General Assembly

9:00-9:20 Is continuous haemoglobin measurement useful?
Azriel Perel, Tel Aviv, Israel

9:20-9:40 Anaemia tolerance in patients with coronary heart disease
Marco Ranucci, Milan, Italy

9:40-10:00 Anaemia tolerance in elderly patients
Jens Meier, Linz, Austria

10:00-10:30 Discussion

9:00-9:20 Coagulopathy of sepsis – time to reconsider anticoagulants?
Jerrold H. Levy, Durham, NC, USA

9:20-9:40 Hospital-acquired thrombosis: a major patient safety issue
Beverley J. Hunt, London, UK

9:40-10:00 VTE prevention: what do the guidelines say?
Charles-Marc Samama, Paris, France

10:00-10:30 Discussion

10:30-11:10 BREAK AND POSTER VISITS

11:10-11:25 Fibrinogen or plasma in trauma – which way to go?
Herbert Schöchl, Vienna, Austria

11:25-11:40 NEVER forget tranexamic acid!
Beverley J. Hunt, London, UK

11:40-11:55 Fibrinogen in high-blood-loss surgery – a must?
Faheez Mohamed, Basingstoke, UK

11:55-12:10 Modern coagulation management – possible without POC devices?
Thorsten Haas, Zurich, Switzerland

12:10-12:40 Discussion

11:10-11:25 Age of blood: do we have all the answers?
Arturo Pereira Saavedra, Barcelona, Spain

11:25-11:40 Which plasma to use in bleeding?
Dania Fischer, Frankfurt, Germany

11:40-11:55 Blood safety issues – what should be tested in 2019?
Peter Schlenke, Graz, Austria

11:55-12:10 Transfusion-associated circulatory overload: increased awareness is needed
Alexander Vlaar, Amsterdam, The Netherlands

12:10-12:40 Discussion

12:40-13:50 Lunchtime industry-sponsored satellite symposia and workshops

13:50-14:30 BREAK AND POSTER VISITS
14:30-14:50  Treatment of preoperative anaemia in cardiac surgery  
   Donat R. Spahn, Zurich, Switzerland

14:50-15:10  Hepcidin – the new golden bullet for iron therapy?  
   Sigismond Lasocki, Angers, France

15:10-15:30  Management of postpartum haemorrhage – NATA consensus statement  
   Jean-François Hardy, Montreal, QC, Canada

15:30-16:00  Discussion

15:10-15:30  Concluding comments  
   Charles-Marc Samama, Paris, France - NATA Chair
THURSDAY, APRIL 4

**E-posters #1-17** Morning break (10:30-11:10)

E-poster station 1, 10:40-11:00 – **Posters 1-4** – T. Frietsch (Germany) & G. Inghilleri (Italy)
E-poster station 2, 10:40-11:05 – **Posters 5-9** – J. Meier (Austria) & J. H. Waters (USA)
E-poster station 3, 10:40-11:00 – **Posters 10-13** – D. Thomas (UK) & B. Froessler (Australia)
E-poster station 4, 10:40-11:00 – **Posters 14-17** – E. Bisbe (Spain) & S. Lasocki (France)

**E-posters #18-34** First afternoon break (13:50-14:30)

E-poster station 1, 14:00-14:20 – **Posters 18-21** – T. Haas (Switzerland) & S. Ozawa (USA)
E-poster station 2, 14:00-14:20 – **Posters 22-25** – B. J. Hunt (UK) & D. Faraoni (Canada)
E-poster station 3, 14:00-14:20 – **Posters 26-29** – M. Muñoz (Spain) & A. Shander (USA)
E-poster station 4, 14:00-14:25 – **Posters 30-34** – J.-F. Hardy (Canada) & J. A. García-Erce (Spain)

**E-posters #36-51** Second afternoon break (16:00-16:40)

E-poster station 1, 16:10-16:30 – **Posters 36-39** – T. Richards (Australia) & D. Faraoni (Canada)
E-poster station 2, 16:10-16:30 – **Posters 40-43** – E. Bisbe (Spain) & T. Frietsch (Germany)
E-poster station 3, 16:10-16:30 – **Posters 44-47** – M. Muñoz (Spain) & M. B. Rondinelli (Italy)
E-poster station 4, 16:10-16:30 – **Posters 48-51** – J. Meier (Austria) & M. Pavesi (Italy)

FRIDAY, APRIL 5

**E-posters #52-70** Morning break (10:30-11:10)

E-poster station 1, 10:40-11:00 – **Posters 52-55** – J.-F. Hardy (Canada) & P. Tibi (USA)
E-poster station 2, 10:40-11:05 – **Posters 56-60** – B. J. Hunt (UK) & M. Ranucci (Italy)
E-poster station 3, 10:40-11:05 – **Posters 61-65** – D. Faraoni (Canada) & A. Vlaar (The Netherlands)
E-poster station 4, 10:40-11:05 – **Posters 66-70** – C.-M. Samama (France) & J. H. Levy (USA)
Blood Transfusion Services / Risks of Transfusion

P01
Quality of blood safety against transfusion transmissible infections in Malawi
R. L. J. Kachala¹, C. Mitambo¹, S. Mbiriyawanda², M. Meke³, B. Mbaya⁴ & I. Nyasulu⁵
¹Malawi Ministry of Health & Population, Lilongwe; ²Department of HIV/AIDS, Malawi Ministry of Health & Population, Lilongwe; ³Global Fund Project Implementation Unit (PIU), Department of HIV/AIDS, Malawi Ministry of Health; ⁴Malawi Blood Transfusion Service (MBTS), Blantyre; ⁵TB/HIV NPO, World Health Organization (WHO), Malawi Office, Lilongwe, Malawi

P02
Safe transfusion-awareness of TRALI and TACO in Serbia
R. Dinić, B. Vasiljević-Jovanović, B. Životić, O. Savić & G. Bogdanović
Blood Transfusion Institute of Serbia, Belgrade, Serbia

Transfusion Practice

P03
Where does the blood go in Northern Ireland?
D. Carson, S. Atkinson & A. McCartney
Northern Ireland Transfusion Committee, Northern Ireland, UK

P04
Allogenic blood transfusion and intensive medicine: results of the transfusion day
M. Recio Anaya¹, K. Nanwani Nanwani², N. Suárez Revira³, A. Serrano Lázaro³, J. A. García-Erce⁴, M. Quintana-Díaz⁵, Grupo de Hemoderivados de la SEMICYUC
¹Servicio de Medicina Intensiva, Complejo Hospitalario Universitario de Jaén, Spain; ²Servicio de Medicina Intensiva, Hospital Universitario La Paz, Madrid, Spain; ³Servicio de Medicina Intensiva, Hospital Universitario Clínico, Valencia, Spain; ⁴Banco de Sangre y Tejidos de Navarra, Spain

P05
Utilization of blood products (a five-year survey): haematology service as a major contributor in increased use of platelets and red blood cells
M. Liker, F. Plenkovic, M. Raos, M. Lukic & B. Golubic-Cepulic
University Hospital Centre Zagreb, Croatia

P06
Anaemia and blood management practice in the setting of an emergency department within a major Australian tertiary hospital
K. Chun Kit Chan¹, M. Clarris¹, C. Town¹², A. Der Avedissian² & K. Wyssussek¹²
¹Royal Brisbane and Women’s Hospital, Brisbane, Australia; ²The University of Queensland, Faculty of Medicine, Brisbane, Australia

P07
The active role of Hospital Transfusion Committee for promoting patient blood management therapy policy in General Hospital Celje
J. Pajk
General Hospital Celje, Celje, Slovenia
Blood Conservation Strategies / Autologous Transfusion

P08
Case study of blood recycling device, Hemafuse, in urban Kenyan surgical theatres
G. Henker & K. Kirsch
Sisu Global Health, Nairobi, Kenya

P09
Do coagulation profiles change in vitro and in vivo post re-infusion of autologous blood collected during caesarean section?
T. R. Tagell1, I. J. Sullivan1, C. S. A. Pritchett2 & C. J. Ralph2
1Blood Transfusion Department; 2Department of Anaesthetics, Royal Cornwall Hospitals NHS Trust, Truro, UK

P10
Cell salvage blood re-infusion following caesarean section: introducing a sticker for recovery notes to improve documentation
M. Beattie1, C. Ralph2 & Z. Amin3
1University of Exeter, Knowledge Spa, 2Anaesthetics Department, 3Obstetrics Department, Royal Cornwall Hospital, Truro, UK

P11
Cell salvage use in major orthopaedic surgery: a retrospective analysis
C. S.athananthan, M. Baldwin, M. J. K. Bankes & E. Aziz
 Guys and St. Thomas Hospital NHS Foundation Trust, London, UK

P12
Evaluation of patient blood management measures in obstetrics – Intraoperative cell salvage (IOCS) and tranexamic acid (TXA)
S. Thomas, E Cairns & C Laxton
Southmead Hospital, North Bristol NHS Trust, UK

P13
Orthopaedic patient blood management
E. Cairns, S. Thomas & C. Laxton
Southmead Hospital, North Bristol Trust, United Kingdom, UK

P14
Applying a patient blood management program in patients undergoing urologic surgery with potential bleeding risk
C. Sáez, M. Barquero, S. Junca & A. Fernández
Parc Taulí Hospital, Sabadell, Spain

P15
Continuous improvement of patient blood management (PBM) in programmed orthopaedic surgery
A. Aranguren1, S. Zalba1, E. Rodríguez Segura2, M. A. Bernal1, M. P. Armendariz1, M. Antelo1, I. Ezepeleta1, J. R. Ortiz & J. A. García-Erce2
1Haematology and Haemotherapy, Complejo Hospitalario de Navarra, 2Clinical Analysis Service Hospital García Orcoyen, 3Bank of Blood and Tissue of Navarra, Pamplona, Spain

P16
Continuous improvement of patient blood management (PBM) in hip replacement (THR) and knee arthroplasty (TKA)
S. Zalba1, A. Aranguren1, I. Plaja1, J. Martínez de Morentín1, M. L. Abinzano2, M. L. Antelo1, J. R. Ortiz & J. A. García Erce1
1Haematology Service Complejo Hospitalario de Navarra, 2Clinical Analysis Service Hospital García Orcoyen, 3Bank of Blood and Tissue of Navarra, Pamplona, Spain

P17
Effect of PBM measures and Enhanced Recovery After Surgery (ERAS) protocols in post-operative outcomes of elective colorectal surgery (POWER Study sub-analysis)*
1Pamplona (Navarra), 2Barcelona, 3Zaragoza, 4Madrid, Spain

P18
Expansion of a patient blood management (PBM) service at a tertiary referral centre with the introduction of a dedicated blood conservation practitioner
C. Laxton, E. Cairns, J. Ashby Styles, K. Mead, S. Thomas & S. Lewis
North Bristol NHS Trust, UK

P19
Patient blood management (PBM) in England – 4 years on
J. Addison, B. Hockley & L. Sherliker
On behalf of the NHS Blood and Transplant/National Blood Transfusion Committee PBM working group
NHS Blood and Transplant, UK

P20
Implementation of “Choosing Wisely” campaign in Norway: Transfusion medicine recommendations from the Norwegian Patient Blood Management (PBM) working group
National Patient Blood Management (PBM) working group, Norway
P21
Severely anaemic patient refusing blood transfusion from religious reasons – the role of PBM
T. Mahecic, M. Mozus, I. Tucic, K. Lojna, D. Karmelic & B. Golubic Cepulic
University Hospital Centre Zagreb, Croatia

P22
Bloodless obstetric surgery in University of Calabar Teaching Hospital
N. Usoro, M. Inyama, I. Ilori & E. Ekanem
University of Calabar Teaching Hospital, Calabar, Nigeria

P23
Iron deficiency alters synaptic integrity in the substantia nigra in the mouse brain
K. Cabolis1, S Albasha2, A. Butcher3, T. Richards3, K. Smith1 & M. Sajic1
1Department of Neuroinflammation, Institute of Neurology, UCL, London, UK, 2Kings College London, UK, 3University of Western Australia, Perth, Australia

P24
Tired of brain fog? Symptoms of patients self-referred for an iron infusion
C. Scott2, S. Abeysiri1, R. Raobaikady2,3 & T. Richards1,2
1University College London, Division for Surgery and Interventional Science, London, UK; 2The Iron Clinic, London, UK; 3Anaesthetic Dept, Royal Marsden Hospital, London, UK

P25
First trimester haemoglobin and maternal morbidity: a prospective cohort study with multivariable analysis
Women’s Health Research Unit, Barts and the London School of Medicine and Dentistry, UK

P26
Iatrogenic anaemia in major cancer surgery
M. Evans, T. Barnes, R. Kanji & R. Raobaikady
Royal Marsden Hospital NHS Foundation Trust, London, UK

P27
Anaemia and blood transfusion in 2 stage spinal surgery
B. Clevenger, S. Lennox & J. Kaur
Royal National Orthopaedic Hospital, Stanmore, UK

P28
The first study of pre-operative anaemia in patients presenting for major surgery to a tertiary hospital in the West of Ireland
J. Kielty & J. McElwain
Department of Anaesthesia, University College Hospital Galway, Galway, Ireland

P29
Calculation of risks associated with preoperative anaemia and the health-economic footprint of patient blood management (PBM)
T. Drabinski
Institut für Mikrodaten-Analyse (IfMDoA) [Institute of Microdata Analysis], Kiel, Germany

P30
The UK cardiac and vascular surgery interventional anaemia response (CAVIAR) study
M. Chau1, T. Richards1, T. Collier1, C. Evans2, S. Abeysiri1, S. Agarwal3 & A. Klein4
1University College London, London, UK; 2Cardiff & Vale University Health Board, Cardiff, UK; 3Manchester Royal Infirmary, Manchester, UK; 4Royal Papworth Hospital, Cambridge, UK

P31
Tearing your hair out about screening for anaemia
S. Abeysiri1, B. Durey4, C. Scott2, M. Chau1, R. Raobaikady2,3 & T. Richards1,2
1University College London, Division for Surgery and Interventional Science, London, UK; 2The Iron Clinic, London, UK; 3Anaesthetic Dept, Royal Marsden Hospital, London, UK

Anaemia Effects and Management
P32
Preoperative screening and treatment of iron-deficiency anaemia - Implementing at a large tertiary referral hospital
M. Gybel-Brask, J. Stensballe, M. Gehren, J. Hillingse & P. I. Johansson
1Sect. for Transfusion Medicine, Capital Region Blood Bank, Rigshospitalet, Copenhagen, Denmark; 2Spine Unit, Dept. of Orthopedic Surgery, Center of Head, Neck and Orthopedics, Rigshospitalet, Copenhagen, Denmark; 3Clinic of Surgical Gastroenterology, Rigshospitalet, Copenhagen Denmark; 4Dept. of Anesthesia, Center of Head, Neck and Orthopedics, Rigshospitalet, Copenhagen, Denmark

P33
The earlier, the better: a real-world experience of peri-operative anaemia management from Royal United Hospital, Bath, UK
M. Jones, H. Maria, S. Scott & S. Wexler
Royal United Hospital NHS Foundation Trust, Bath, UK

P34
Assessing iron deficiency anaemia before surgery: Can we do better?
M. Roets, T. An & K. Wyssusek
Royal Brisbane and Women’s Hospital (RBWH), Brisbane, Queensland, Australia

P35
Abstract withdrawn

P36
Optimising anaemia with intravenous iron before major surgery
R. C. F Sinclair, J de Pennington & K. E. Duffield
On behalf of Preoperative Assessment Clinic, Department of Anaesthesia, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK

P37
Scottish consensus on the management of preoperative anaemia
S. McKinlay & C. Beacroft, on behalf of the Scottish Perioperative Medicine Leads Anaemia Workstream
1Consultant Anaesthetist and Clinical Lead for Perioperative Medicine, Glasgow Royal Infirmary, Glasgow G4 0SF, Scotland, UK; 2Consultant Anaesthetist and Clinical Lead for Perioperative Medicine, Ninewells Hospital, Dundee, Scotland, UK

P38
The impact of the international consensus on pre-operative management of anaemia and iron deficiency in an urban colorectal surgical population in the United Kingdom
C. Lees, R. West, J. Williams & C. Pritchard
Buckinghamshire NHS Trust, Buckinghamshire, United Kingdom, UK

P39
Intravenous iron infusion services in a tertiary cancer centre: a year in review
M. Evans, A. Hegarty, E. Black & R. Raobaikady
The Royal Marsden Hospital NHS Foundation Trust, London, UK

P40
Peri-operative anaemia management: a real-world experience of the Intravenous (IV) Iron Service at the Surgical Day Unit, University Hospital Southampton, UK
L. Sheppard, J. Plumb & M. Wakatsuki
University Hospital Southampton NHS Foundation Trust, Southampton, UK

P41
The management of preoperative anaemia in cardiac surgery patients: A retrospective data analysis
C. Quarterman1 & S. Agarwal2
1Liverpool Heart and Chest Hospital; 2Manchester University Hospital, UK

P42
Optimising outpatient intravenous iron therapy and efficiency in a Day Clinical Centre. Audit of iron isomaltoside therapy in a district general hospital in Northern Ireland
A. Cullen
Craigavon Area Hospital, Portadown, Northern Ireland, UK

P43
Optimising iron therapy and efficiency for surgical patients in a Day Clinical Centre. Audit of iron isomaltoside therapy in preoperative patients in a district general hospital in Northern Ireland
A. Cullen
Craigavon Area Hospital, Portadown, Northern Ireland, UK

P44
Treatment of preoperative anaemia with high IV iron dose
Hospital Universitario Central de Asturias, Asturias, Spain

P45
Pre-operative IV iron infusion clinic – a patient experience survey
R. Horner, J. Trattles & L. Roberts
Sunderland Royal Hospital, Sunderland, UK
**P46**
Pre-operative anaemia management for total joint arthroplasty (TJA) reduces post-operative blood transfusions and length of stay (LOS)
R. Horner, L. Roberts & J. Trattles
Sunderland Royal Hospital, Sunderland, UK

**P47**
Incidence and management of perioperative anaemia and iron deficiency in orthopaedic surgery
S. Zalba1, A. Aranguren1, E. Martin1, E. Ongay2, B. Apesteguia3, M.L. Antelo1 & J.A. García Erce4
1Hematology Service Complejo Hospitalario de Navarra; 2Clinical Analysis Service Hospital García Orcoyen; 3Bank of Blood and Tissue of Navarra, Spain

**P48**
‘Iron’ing out the creases: A service evaluation of the real-world efficacy of a pre-operative oral and intravenous iron pathway in a UK District General Hospital for patients undergoing elective primary and revision hip and knee arthroplasty
Department of Peri-Operative Medicine and Anaesthesia, Torbay Hospital, Torbay and South Devon NHS Foundation Trust, Devon, UK

**P49**
Postoperative outcome following hip and in knee arthroplasty in non-anaemic iron replete patients treated with intravenous iron carboxymaltose supplementation vs control
T. D’Amato, G. Borello, M. Bovio, C. Cianchi, G. Fenocchio, F. Martorelli, G. Monteleone, V. Simili & M. Scardino
Humanitas Research Hospital Milano, Italy

**P50**
Efficacy and safety of intravenous iron as an alternative to blood transfusion in chronic very severe anaemias without hospitalization. When the practice overcomes the guidelines
1Legnano, Italy; 2Barcelona, Spain; 3Madrid, Spain; 4Bolzano, Italy; 5Rome, Italy; 6Zaragoza, Spain; 7Navarra, Spain

**P51**
Pooled analysis of the PHOSPHARE-IDA 04/05 studies: findings relevant to respiratory muscle function
H. Zoller1, P. Schaffalitzky de Muckadell2 & M. Wolf3
1Medical University of Innsbruck, Innsbruck, Austria; 2Pharmacosmos A/S, Holbaek, Denmark; 3Duke University School of Medicine, Durham, North Carolina, USA

---

**Haemostasis & Thrombosis**

**P53**
Introduction of a formal bleeding assessment into use in pre-admission surgical clinic
B. Thorp, D. Behan & J. Joseph
Department of Haematology, St Vincent’s Hospital, Sydney, Australia

**P54**
Advantages of automatic detection of platelet dysfunction
B. Komatina & M. Paunović
Clinical Hospital Center “Zvezdara”, Belgrade, Serbia

**P55**
Should we implement platelet function assessment as a strategy of patient blood management in cardiac surgery
R. Lopes, M. Alves, S. Fevereiro, J. Varandas & M. Chaves
Hospital de Santa Cruz (HSC), Lisbon, Portugal

**P56**
Improved patient outcomes and blood product management in surgical settings with thromboelastography-guided haemostatic therapy: systematic review and analysis
J. D. Dias1, A. Sauaia2, H. E. Achnacco1, J. Hartmann3 & E. E. Moore4
1Haemonetics S.A., Signy, Switzerland; 2University of Colorado Denver, Denver, USA; 3Haemonetics Corporation, Braintree, USA

**P57**
Dynamic functional clot formation in patients undergoing endoscopic mucosal resection
N. Aboustate1,2, L. Zorrón Cheng Tao Pu3, A. Ovenden2, R. Singh3 & B. Froessler1,2
1Discipline of Acute Care Medicine at Adelaide Medical School, University of Adelaide, South Australia; 2Dept of Anaesthesia, 3Dept of Gastroenterology, Lyell McEwin Hospital (LMH), Elizabeth Vale, SA, Australia
P58
Improvement in patient treatment with blood components after introduction of Rotem analysis
L. Lokar
Center for Transfusion Medicine, University Medical Centre Maribor, Slovenia

P59
Bleeding in cardiovascular surgery: Impact of interdisciplinary protocollization
A. B. Vilaseca¹, G. L. Vidmar¹, R. F. Barbera²; G. Bastianelli³ & E. R. Furszyfer⁴
Departments of ¹Hematology, ²Internal Medicine, ³Cardiovascular Surgery, ⁴Anesthesiology, Clínica San Camilo, Buenos Aires, Argentina

P60
Efficacy and safety of fibrinogen concentrate vs cryoprecipitate in pseudomyxoma peritonei surgery: a prospective, randomised, controlled phase 2 study
A. Roy¹, N. Sargant¹, S. Rangarajan¹, S. Alves¹, J. Bell¹, S. Stanford¹, C. Solomon², I. Kruzikova², S. Knaut² & F. Mohamed³
¹Basingstoke and North Hampshire Hospital, Hampshire, UK; ²Octapharma AG, Lachen, Switzerland

P61
Experience with factor XIII concentrate administration following acquired factor XIII deficiency in a tertiary university children’s hospital
M. M. Cushing¹ & T. Haas²
¹Transfusion Medicine and Cellular Therapy, Weill Cornell Medicine, New York, NY, USA; ²Department of Anesthesia, University Children’s Hospital Zurich, Switzerland

P62
Tranexamic acid administration in total hip arthroplasty within a blood patient management programme
Hospital Universitario Severo Ochoa, Madrid, Spain

P63
Transfusion rate in a monographic hospital of orthopaedic surgery after implementing a protocol of perioperative use of tranexamic acid
Hospital Complex of Navarra, Pamplona, Spain

P64
Transfusion rate in hip prosthetic surgery after implementing a protocol of perioperative use of tranexamic acid
Hospital Complex of Navarra, Pamplona, Spain

P65
Transfusion rate in prosthetic knee surgery after implementing a protocol of perioperative use of tranexamic acid
Hospital Complex of Navarra, Pamplona, Spain

P66
Use of a fibrin sealant (EVICEL®) within a blood-saving protocol in patients undergoing total hip arthroplasty revision: effects on post-operative blood transfusion and health-care related cost analysis
M. Scardino, F. Martorelli, G. Fenocchio & G. Grappiolo
Humanitas Research Hospital, Rozzano, Italy

P67
Heparin induced thrombocytopenia in critical ill patient. Case report
F. Sabiá¹, M. Pereira², E. Gomes², S. Faria¹, R. Araújo² & S. Sousa¹
¹Immunohemotherapy Department, ²Critical Care Unit, Unidade Local de Saúde de Matosinhos. Hospital Pedro Hispano, EPE, Porto, Portugal

P68
Impact of direct oral anticoagulant therapy on the management of hip fracture patients
N. Gautier, A. Pirson, P. Van Der Linden & J.-P. Lechat
Grand Hôpital de Charleroi, Charleroi, Belgium

P69
Pharmacokinetics of enoxaparin after coronary artery bypass grafting. Randomized clinical trial
M. Parviainen, A. Vahtera, H. Huhtala, A. Kuitunen & K. Järvelä
Tampere University Heart Hospital, Tampere, Finland

P70
A systematic review and meta-analysis of incidence of venous thromboembolism in pregnancy
J. Daru, A. Asour, F. E. T. Shiers-Gelalis, E. Oliver, F. Aktar, E. Rogozinska, B. Hunt & S. Thangaratinam
Women’s Health Research Unit, Barts and the London School of Medicine and Dentistry, UK
A single source for international hematology research and clinical practice since 1948

Acta Haematologica

Seven reasons to publish with us

• Rapid peer-review process
• Articles are published online within 4 weeks of acceptance
• Listed in PubMed/Medline
• Possibility to integrate your ORCID identifier
• Online supplementary material available via Figshare
• Tables and figures available as PowerPoint slides for use in presentations
• Track shares and engagements of your article with Altmetric

Acta Haematologica is a well-established and internationally recognized clinically-oriented journal with a prominent Editorial Board featuring balanced, wide-ranging coverage of current hematology research. It contains a wealth of information on such problems as anemia, blood coagulation abnormalities, acute and chronic leukemias, Hodgkin and non-Hodgkin lymphomas, multiple myeloma and paraproteinemias as well as rare and hereditary hematological disorders.

Editor-in-Chief
P. Raanani, Petah Tikva

www.karger.com/aha
### SATELLITE SYMPOSIUM – Supported by Masimo

**NEW HORIZONS IN PATIENT BLOOD MANAGEMENT; NEW INSIGHTS AND NEW CHALLENGES – “PEARLS OF WISDOM”**

Chair: Aryeh Shander, Englewood, NJ, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:10-13:30</td>
<td>Getting it right first! – Patient blood management (PBM) in surgical patients: the importance of anaemia in patients undergoing surgery. Sigismond Lasocki, Angers, France</td>
</tr>
<tr>
<td>13:30-13:50</td>
<td>Iatrogenic haemodilution during fluid administration: do we need to redefine our haemodynamic goals? Azriel Perel, Tel Aviv, Israel</td>
</tr>
</tbody>
</table>

### SPONSORED LECTURE – Supported by Fresenius Kabi

**OVERVIEW OF NEW GUIDELINES AND QUALITY MANAGEMENT IN CELL SALVAGE – AN UPDATE**

Speaker: Patrick Meybohm, Frankfurt, Germany

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:50-13:10</td>
<td>Lecture</td>
</tr>
<tr>
<td>13:10-13:20</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

### WORKSHOP – WETLAB

**FUNCTIONAL HAEMOSTATIC MONITORING: A HANDS-ON WORKSHOP FOR BEGINNERS**

Chairs: Thomas Frietsch, Mannheim, Germany - Marco Ranucci, Milan, Italy - Herbert Schöchl, Vienna, Austria

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:50-13:10</td>
<td>SEER sonorheometry Marco Ranucci, Milan, Italy Todd Allen, Charlottesville, VA, USA (Hemosonics representative)</td>
</tr>
<tr>
<td></td>
<td>Rotational thromboelastometry Thomas Frietsch, Mannheim, Germany Klaus Görlinger, Munich, Germany (Instrumentation Laboratory representative)</td>
</tr>
<tr>
<td></td>
<td>Thromboelastography Herbert Schöchl, Vienna, Austria João Dias, Signy, Switzerland (Haemonetics representative)</td>
</tr>
</tbody>
</table>

*Workshop with free pre-registration. Maximum number of participants: 50*
### SATELLITE SYMPOSIUM – Supported by CSL Behring

**GOAL-DIRECTED THERAPY OF BLEEDING**
Chair: Jens Meier, Linz, Austria

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:50-13:15| In emergency patients  
Herbert Schöchl, Vienna, Austria |
| 13:15-13:40| In perioperative setting  
Daniel Dirkmann, Essen, Germany |
| 13:40-13:50| Discussion |

### WORKSHOP – WETLAB

**FUNCTIONAL HAEMOSTATIC MONITORING: A HANDS-ON WORKSHOP FOR ADVANCED USERS**
Chairs: Thomas Frietsch, Mannheim, Germany - Oliver Grottke, Aachen, Germany - Marco Ranucci, Milan, Italy

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:50-13:50| **SEER sonorheometry**  
Marco Ranucci, Milan, Italy  
Todd Allen, Charlottesville, VA, USA (Hemosonics representative) |
|            | **Rotational thromboelastometry**  
Thomas Frietsch, Mannheim, Germany  
Klaus Görlinger, Munich, Germany (Instrumentation Laboratory representative) |
|            | **Thromboelastography**  
Oliver Grottke, Aachen, Germany  
João Dias, Signy, Switzerland (Haemonetics representative) |

*Workshop with free pre-registration. Maximum number of participants: 50*
Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems. In the field of biosimilars, Fresenius Kabi develops products with a focus on oncology and autoimmune diseases. With its corporate philosophy of “caring for life”, the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face. For more information, please visit www.fresenius-kabi.com.

ClotPro® viscoelastometry provides a rapid and comprehensive overview of the blood coagulation system. It offers a unique combination of ease of use, flexibility, and throughput (6 channels for parallel testing of different samples). ClotPro’s active-tip technology eliminates any reagent handling and delivers a best in class tests menu, including established viscoelastic screening assays (EX-, FIB-, IN-, AP-, HI-, NA-test) and new assays for the monitoring of DOACs and lysis resistance (RVV-, ECA-, TPA-test). For more information, take a look at www.clot.pro.

CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ needs using the latest technologies to develop and deliver innovative therapies. The company offers the broadest range of products in the industry for treating coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. CSL Behring’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.

The company operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL; USOTC:CLLY), headquartered in Melbourne, Australia, employs nearly 20,000 people, providing life-saving therapies to people in more than 60 countries. For more information visit www.cslehring.com and follow us on www.Twitter.com/CSLBehring.

Hemostasis Analyzer is a next-generation viscoelastic diagnostic platform that provides actionable and easy to interpret information to guide the management of critical bleeding. This enables clinicians to choose the right treatment in the right time frame, dramatically improving outcomes. Our innovative in vitro diagnostic platform characterizes hemostasis – the balance between bleeding and clotting – in a variety of acute care clinical settings. The Quantra is CE marked and is currently IUD in the US, check hemosonics.com for updates.

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics visit our web site at http://www.haemonetics.com.

LivaNova seeks to transform the way clinicians manage coagulation dysfunctions by providing comprehensive, timely information on coagulation status at the point of care. The novel Quantra® Hemostasis Analyzer is a next-generation viscoelastic diagnostic platform that provides actionable and easy to interpret information to guide the management of critical bleeding. This enables clinicians to choose the right treatment in the right time frame, dramatically improving outcomes. Our innovative in vitro diagnostic platform characterizes hemostasis – the balance between bleeding and clotting – in a variety of acute care clinical settings. The Quantra is CE marked and is currently IUD in the US, check hemosonics.com for updates.

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London, LivaNova has a presence in more than 100 countries worldwide. The Company currently employs more than 3,500 employees. LivaNova operates as two business franchises: Cardiac Surgery and Neuromodulation, with operating headquarters in Mirandola (Italy) and Houston (U.S.A.), respectively.
Masimo is a global leader in innovative noninvasive monitoring technologies, including medical devices, a wide array of sensors, and connectivity solutions. In 1995, Masimo debuted SET® Measure-through Motion and Low Perfusion™ pulse oximetry, estimated to be used on more than 100 million patients annually. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry, allowing noninvasive and continuous monitoring of additional physiologic parameters that previously could only be measured invasively, such as total hemoglobin (SpHb®). We continue to advance noninvasive monitoring with innovations like Root®, Radius-7®, and Rad-97™, while expanding into new markets with SedLine® brain monitoring, NomoLine™ capnography, and automation and connectivity solutions such as Patient SafetyNet™.

Masimo is a global leader in innovative noninvasive monitoring technologies, including medical devices, a wide array of sensors, and connectivity solutions. In 1995, Masimo debuted SET® Measure-through Motion and Low Perfusion™ pulse oximetry, estimated to be used on more than 100 million patients annually. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry, allowing noninvasive and continuous monitoring of additional physiologic parameters that previously could only be measured invasively, such as total hemoglobin (SpHb®). We continue to advance noninvasive monitoring with innovations like Root®, Radius-7®, and Rad-97™, while expanding into new markets with SedLine® brain monitoring, NomoLine™ capnography, and automation and connectivity solutions such as Patient SafetyNet™.

We continue to advance noninvasive monitoring with innovations like Root®, Radius-7®, and Rad-97™, while expanding into new markets with SedLine® brain monitoring, NomoLine™ capnography, and automation and connectivity solutions such as Patient SafetyNet™.

At Pharmacosmos, we are specialists in iron therapy. We develop, manufacture and market medicines for the treatment of iron deficiency anaemia in humans and animals. We are furthermore specialists in developing and producing advanced carbohydrates for pharmaceutical and technical uses. Across the world, more than 1 billion people live with iron deficiency anaemia, making it one of the largest global health challenges of our time. At Pharmacosmos, we want to change the way iron deficiency is prevented and treated in humans and animals. We are inspired by one central question: How can we continue to improve patient safety, recovery and convenience and thereby achieve better outcomes?

We seek the answer by staying at the scientific forefront of iron and carbohydrate technology — partnering with dedicated people and leading organisations to deliver the best possible treatments for human and veterinary use. In this way, we improve more than iron complexes and carbohydrates, we improve the quality of lives.

We have our headquarters in Holbaek, Denmark and affiliates in the US, UK, Ireland, Germany, Denmark, Sweden and Norway.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative medical devices, handling the entire production process, from proprietary raw materials to finished product. PharmaNutra follows rigorous quality standards, always making careful selection of raw materials one of its top priorities. The efficacy of the products has been demonstrated by numerous pre-clinical and clinical studies. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of Pharmaceutical Representatives as medical details. PharmaNutra’s Products are sold in over 70 countries abroad, through 35 selected partners. PharmaNutra leads the market in the production and marketing of iron-based nutritional supplements under the SiderAL brand, where it boasts a number of important patents on sucrosomial® technology. Over the years, the Group focused on a precise intellectual property strategy, founded on the integrated management of the whole manufacturing and market chain: proprietary raw materials, patents, brands and scientific evidences. http://www.PharmaNutra.it.

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma. Vifor Pharma Group is headquartered in Switzerland.
ATHENS
APRIL 23-24, 2020

21st ANNUAL SYMPOSIUM
on Patient Blood Management, Haemostasis and Thrombosis

#NATAforum
www.nataonline.com
New Horizons in Patient Blood Management; New Insights and New Challenges – “Pearls of Wisdom”

Location: Main Auditorium, Maritim proArte Hotel Berlin, Germany

Date and Time: Thursday April 4th • 12:50 - 13:50
Lunch will be provided

Chairperson: Prof. Aryeh Shander, MD, FCCM, FCCP

Presenters


*Aryeh Shander, MD, FCCM, FCCP, FASA*
Emeritus Chair, Department of Anesthesiology, Critical Care Medicine, Pain Management and Hyperbaric Medicine
Director TEAMHealth Research Institute
Executive Medical Director
Institute for Patient Blood Management and Bloodless Medicine and Surgery
Englewood Hospital and Medical Center
Englewood, New Jersey
Clinical Professor of Anesthesiology, Medicine and Surgery
Icahn School of Medicine at Mount Sinai
New York, New York
Clinical Professor of Anesthesiology
Rutgers School of Medicine
Newark, New Jersey

**Getting It Right First! – Patient Blood Management (PBM) in Surgical Patients: The Importance of Anaemia in Patients Undergoing Surgery**

*Sigismond Lasocki, MD, PhD*
Professor of Anesthesiology and Intensive Care,
Chief Department of Anesthesiology and Intensive Care
Chairman - Pôle ASUR (Anesthésie SAMU Urgences Réanimation), CHU Angers
Angers, France

**Iatrogenic Haemodilution During Fluid Administration: Do We Need To Re-define Our Haemodynamic Goals?**

*Azriel Perel, MD*
Professor of Anesthesiology and Intensive Care
Department of Anesthesiology and Intensive Care
Sheba Medical Center, Tel Aviv University
Tel Aviv, Israel